九强生物：产品“果糖胺测定试剂盒”取得注册证

Group 1 - The core point of the article is that Jiukang Bio has received a medical device registration certificate for its "fructosamine testing kit" from the Beijing Drug Administration [1] - Jiukang Bio's revenue composition for the year 2024 is projected to be 100% from the healthcare sector [1] Group 2 - As of the report, Jiukang Bio has a market capitalization of 7.7 billion yuan [2] - There are concerns regarding the financial practices of related parties associated with Jiangsu Wuzhong, which may impact investor confidence [2]